期刊文献+

湖北省宜昌市2019-2020年20岁及以下人群水痘-带状疱疹病毒基因特征分析

Genetic characterization of varicella-zoster virus in people aged 20 years and under in Yichang City of Hubei Province,2019-2020
原文传递
导出
摘要 目的分析2019-2020年湖北省宜昌市≤20岁人群水痘-带状疱疹病毒(VZV)基因特征。方法依托宜昌市健康管理大数据平台,对2019年3月至2020年9月在湖北省宜昌市3家医院就诊并被临床诊断为带状疱疹的≤20岁病例开展调查。采集病例疱疹液、咽拭子标本并完成问卷调查以获得基本信息。采用实时荧光定量PCR方法进行病毒阳性鉴定,采用PCR方法扩增VZV开放阅读框(ORF)并对产物进行测序,分析单核苷酸多态性位点的突变情况,确定VZV基因型别。结果46例带状疱疹患者中,男女性别比为1.3∶1(26∶20),年龄范围7~20岁。15例患者有水痘疫苗接种史,其中接种1和2剂次分别有13和2例。VZV阳性率为73.91%(34/46),基因型均为Clade 2遗传支。且ORF22基因核苷酸序列系统进化树分析显示,34株标本与Clade 2代表株核苷酸序列匹配度为99.0%~100.0%。结论2019-2020年宜昌市≤20岁人群带状疱疹的VZV主要流行株型别为Clade 2遗传支。 Objective To analyze the genetic characteristics of varicella-zoster virus(VZV)in people aged 20 years and under in Yichang City of Hubei Province from 2019 to 2020.Methods Based on the Yichang Health Big Data Platform,we investigated cases 20 and under clinically diagnosed as herpes zoster in three hospitals from March 2019 to September 2020.Collecting vesicle fluid and throat swab samples of the cases and completing questionnaires to obtain basic information.Real-time fluorescent quantitative PCR was used for positive identification of the virus.PCR amplification of VZV's open reading frame(ORF)and sequencing of the products to determine the VZV genotype.Analyze mutations at some specific single nucleotide polymorphism(SNP)sites.Results Among 46 cases of herpes zoster,the male to female ratio was 1.3∶1(26∶20)and the age ranged from 7 to 20 years old.Fifteen cases had been vaccinated against varicella,including 13 and 2 cases of 1 and 2 doses,respectively.VZV strains were detected in 34 samples(73.91%),all belonging to Clade 2.Phylogenetic tree analysis of the nucleotide of ORF22 showed,compared with Clade 2 referenced strains,the sequence matching degree of nucleotide for all 34 samples was 99.0%to 100.0%.Conclusion The main VZV strain causing herpes zoster in people aged 20 years and under in Yichang from 2019 to 2020 was Clade 2.
作者 尤美莹 王苗苗 郭宏 王天奇 李旭东 许松涛 胡跃华 殷大鹏 You Meiying;Wang Miaomiao;Guo Hong;Wang Tianqi;Li Xudong;Xu Songtao;Hu Yuehua;Yin Dapeng(Office of Epidemiology,Chinese Center for Disease Control and Prevention,Beijing 102206,China;National Health Commision Key Laboratory of Medical Virology and Viral Diseases,National Institute for Viral Disease Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing 102206,China;Data Resources and Statistics Department,Beijing Municipal Health Big Data and Policy Research Center,Beijing 100034,China;Hainan Center for Disease Control and Prevention,Haikou 570203,China)
出处 《中华流行病学杂志》 CAS CSCD 北大核心 2023年第4期607-610,共4页 Chinese Journal of Epidemiology
基金 北京市自然科学基金(L202008)。
关键词 水痘-带状疱疹病毒 带状疱疹 基因特征 Varicella-zoster virus Herpes zoster Genetic characteristics
  • 相关文献

参考文献7

二级参考文献83

  • 1杜鹏,李龙.新时代中国人口老龄化长期趋势预测[J].中国人民大学学报,2021,35(1):96-109. 被引量:232
  • 2Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster [J]. J Clin Virol, 2010, 48(Suppl 1): S2-S7.
  • 3Oliver SL, Sommer MH, Reichelt M, Rajamani J, Vlaycheva-Beisheim L, Stamatis S, Cheng J, Jones C, Zehnder J, Arvin AM. Mutagenesis of varicella-zoster virus glycoprotein I (gI) identifies a cysteine residue critical for gE/gI heterodimer formation, gI structure, and virulence in skin cells [J]. J Virol, 2011, 85(9): 4095-4110.
  • 4Leroux-Roels I, Leroux-Roels G, Clement F, Vandepapeli:re P, Vassilev V, Ledent E, Heineman TC. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein E subunit vaccine candidate in young and older adults [J]. J Infect Dis, 2012, 206(8): 1280-1290.
  • 5Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales [J]. Vaccine, 2001, 19 (23-24): 3076-3090.
  • 6Gauthier A, Breuer J, Carrington D, Martin M, R6my V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom [J]. Epidemiol Infect, 2009, 137(1): 38-47.
  • 7Gershon AA, Steinberg SP, Gelb L, Galasso G, Borkowsky W, LaRussa P, Farrara A. Live attenuated varicella vaccine. Efficacy for children with leukemia in remission [J]. JAMA, 1984, 252(3): 355-362.
  • 8Levin MJ, Gershon AA, Weinberg A, Song LY, Fentin T, Nowak B; Pediatric AIDS Clinical Trials Group 265 Team. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4+T cells [J]. J Infect Dis, 2006, 194(2): 247-255.
  • 9Reynolds MA, Chaves SS, Harpaz R, Lopez AS, Seward JF. The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review [J]. J Infect Dis, 2008, 197(Suppl 2) : S224-S227.
  • 10Macartney KK, Burgess MA. Varicella vaccination in Australia and New Zealand [J]. J Infect Dis, 2008, 197 (Suppl 2) : S191-S195.

共引文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部